Cerebral palsy is not a specific genetically determined biomedical condition like Duchenne muscular dystrophy.The term encompasses a group of conditions that have in common an impairment in brain function or structure that causes an enduring impairment in the development of motor control, often (but not invariably) with additional central nervous system impairments such as epilepsy, learning disabilities and sensory difficulties.
About
- Cerebral palsy comprises a range of non-progressive neurological impairments, present from the time of birth or arising in early childhood.
- Damage to the central nervous system manifests as a chronic motor disorder with stationary dynamics
- Often in conjunction with cognitive issues, epilepsy, sensory difficulties
Epidemiologic and genetic risk factors for cerebral palsy
- Prevalence: 2 in 1000 people
- Preterm delivery
- Coexisting congenital anomaly (maldevelopment)
- Probable genetic causes
- Bacterial and viral intrauterine infection
- Altered fetal inflammatory or thrombophilic response (perinatal stroke)
- Fetal growth restriction
- Higher-order pregnancy, risk greater with monozygosity and in vitro fertilization
- Tight nuchal umbilical cord
- Prolonged shoulder dystocia
- Placental pathology, eg, chorioamnionitis, Villitis
- Inborn errors of metabolism
- Male:female ratio 1.3:1
Clinical Types
Clinical Types
- Spastic hemiplegic: weakness along one side
- Spastic diplegic: Spastic muscles are tight and stiff
- Spastic quadriplegic: Spastic muscles are tight and stiff
- Athetoid form of cerebral palsy: Athetosis is slow, writhing movements, particularly in the hands and feet
- Sphincter and autonomic dysfunction
Investigations
- Brain Imaging
- EEG
- Genetic testing
Prevention
- Maternal vaccinations
- Folate
- Avoid smoking, alcohol, other drugs
Management
- The long-held belief that most or many cases of CP are due to trauma or asphyxia around the time of birth and that earlier intervention can prevent the neuropathology is not evidence based
- Generalised support, adaptations and therapy. Orthotics, Casts and Splints Involvement of PT/OT and SLT can help. Educational support. The goal is independent living if possible depending on the deficits. A huge number of specialists may be involved.
- Steroids improve muscle strength and are frequently used, but carry an increased risk of osteoporosis and vertebral fractures
- New Drugs - Ataluren. Increases binding of transfer RNA (tRNA) molecules at the site of stop codons with a mismatch in one base (near-cognate tRNAs). These cause a full-length protein to be produced with an amino acid substitution rather than a truncated non-functional protein.
- Botulinum toxin has been used for focal areas of spasticity. Baclofen and other agents may be trialled.
References